Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2018 Dec 31:2018:3652602.
doi: 10.1155/2018/3652602. eCollection 2018.

Breast Cancer Development in a Transgender Male Receiving Testosterone Therapy

Nadia Barghouthi  1 , Jennifer Turner  2 , Jessica Perini  1
Affiliations
Case Reports

Breast Cancer Development in a Transgender Male Receiving Testosterone Therapy

Nadia Barghouthi et al. Case Rep Endocrinol. .

Abstract

Context: To describe a case of invasive ductal carcinoma of the breast in a transgender male receiving testosterone therapy for gender-affirming treatment.

Case description: A 28-year-old transgender male receiving intramuscular testosterone was found to have a breast mass on ultrasound after self-exam revealed a palpable breast lump. Ultrasound-guided breast biopsy revealed estrogen receptor/progesterone receptor (ER/PR) negative, human epidermal growth factor receptor-2 (HER-2) positive, invasive ductal carcinoma of the left breast. He underwent neoadjuvant and adjuvant chemotherapy along with bilateral mastectomy. At patient request, his testosterone injections were permanently discontinued.

Conclusion: Fewer than 20 cases of breast cancer in transgender male patients have been reported in medical literature. While studies have shown increased risk of breast cancer in postmenopausal women with higher testosterone levels, data regarding premenopausal women is conflicting and little is known about breast cancer risk in transgender individuals receiving gender-affirming hormone therapy (GAHT), with inconclusive results regarding correlation between testosterone therapy and breast cancer. More research is required to evaluate whether a possible increased risk of breast cancer exists for transgender men receiving gender-affirming therapy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Breast ultrasound: lobulated solid left breast mass at 11:00, approximately 0.8 × 1.1 × 1.4 cm.
See this image and copyright information in PMC

References

    1. Yager J. D., Davidson N. E. Estrogen carcinogenesis in breast cancer. The New England Journal of Medicine. 2006;354(3):270–282. doi: 10.1056/nejmra050776. - DOI - PubMed
    1. Eliassen A. H., Missmer S. A., Tworoger S. S., et al. Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. Journal of the National Cancer Institute. 2006;98(19):1406–1415. doi: 10.1093/jnci/djj376. - DOI - PubMed
    1. Shao T., Grossbard M. L., Klein P. Breast cancer in female-to-male transsexuals: Two cases with a review of physiology and management. Clinical Breast Cancer. 2011;11(6):417–419. doi: 10.1016/j.clbc.2011.06.006. - DOI - PubMed
    1. Burcombe R. J., Makris A., Pittam M., Finer N. Breast cancer after bilateral subcutaneous mastectomy in a female-to-male trans-sexual. The Breast. 2003;12(4):290–293. doi: 10.1016/S0960-9776(03)00033-X. - DOI - PubMed
    1. Nikolic D. V., Djordjevic M. L., Granic M., et al. Importance of revealing a rare case of breast cancer in a female to male transsexual after bilateral mastectomy. World Journal of Surgical Oncology. 2012;10, article no. 280 doi: 10.1186/1477-7819-10-280. - DOI - PMC - PubMed

Publication types